| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| OKUR - OKUR | HOLD | 0 @ USD 2.83077 | USD 0 | The current share valuation price of OKUR based on adjusted close was USD 2.83077. The average price that OKUR shares were previous bought at was USD 5.61305. The current market price is -49.6% lower than average price they were purchased at. The value of the holding in OKUR has fallen by USD 25 compared to the previous valuation of OKUR |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-12-23 this would crystalise an overall loss. |
| FATE - Fate Therapeutics Inc | SELL | -1,357 @ USD 0.976881 | USD -1,326 | The ETF sold 1357 shares of FATE on 2025-12-23. The shares were previously bought for an average price of USD 1.14824. The Fate Therapeutics Inc shares were sold for -14.9% lower than average price of previous purchases. This resulted in an overall loss of USD 233 The average price that the ETF previously sold FATE share for is USD 1.04629 which is higher than the selling price of USD 0.976881 on 2025-12-23. |
| CRBU - Caribou Biosciences Inc | SELL | -884 @ USD 1.66 | USD -1,467 | The ETF sold 884 shares of CRBU on 2025-12-23. The shares were previously bought for an average price of USD 1.72. The Caribou Biosciences Inc shares were sold for -3.5% lower than average price of previous purchases. This resulted in an overall loss of USD 53 The average price that the ETF previously sold CRBU share for is USD 2.02058 which is higher than the selling price of USD 1.66 on 2025-12-23. |
| ARCT - Arcturus Therapeutics Holdings Inc | SELL | -588 @ USD 6.42999 | USD -3,781 | The ETF sold 588 shares of ARCT on 2025-12-23. The shares were previously bought for an average price of USD 12.5039. The Arcturus Therapeutics Holdings Inc shares were sold for -48.6% lower than average price of previous purchases. This resulted in an overall loss of USD 3,571 The average price that the ETF previously sold ARCT share for is USD 13.8555 which is higher than the selling price of USD 6.42999 on 2025-12-23. |
| HUMA - Humacyte Inc | SELL | -3,396 @ USD 1.13 | USD -3,837 | The ETF sold 3396 shares of HUMA on 2025-12-23. The shares were previously bought for an average price of USD 1.98092. The Humacyte Inc shares were sold for -43.0% lower than average price of previous purchases. This resulted in an overall loss of USD 2,890 The average price that the ETF previously sold HUMA share for is USD 2.67517 which is higher than the selling price of USD 1.13 on 2025-12-23. |
| CABA - Cabaletta Bio Inc | SELL | -1,884 @ USD 2.18 | USD -4,107 | The ETF sold 1884 shares of CABA on 2025-12-23. The shares were previously bought for an average price of USD . The Cabaletta Bio Inc shares were sold for 0.0% than average price of previous purchases. The average price that the ETF previously sold CABA share for is USD 2.91235 which is higher than the selling price of USD 2.18 on 2025-12-23. |
| VYGR - Voyager Therapeutics Inc | SELL | -1,068 @ USD 3.99001 | USD -4,261 | The ETF sold 1068 shares of VYGR on 2025-12-23. The shares were previously bought for an average price of USD 3.94785. The Voyager Therapeutics Inc shares were sold for 1.1% higher than average price of previous purchases. This sale made a profit of USD 45 The average price that the ETF previously sold VYGR share for is USD 4.71774 which is higher than the selling price of USD 3.99001 on 2025-12-23. |
| EDIT - Editas Medicine Inc | SELL | -1,992 @ USD 2.19001 | USD -4,362 | The ETF sold 1992 shares of EDIT on 2025-12-23. The shares were previously bought for an average price of USD 2.61421. The Editas Medicine Inc shares were sold for -16.2% lower than average price of previous purchases. This resulted in an overall loss of USD 845 The average price that the ETF previously sold EDIT share for is USD 2.01584 so the ETF has sold 1992 shares on 2025-12-23 at a higher price than the previous selling average. |
| OABI - OmniAb Inc. | SELL | -2,580 @ USD 1.94 | USD -5,005 | The ETF sold 2580 shares of OABI on 2025-12-23. The shares were previously bought for an average price of USD 1.88466. The OmniAb Inc. shares were sold for 2.9% higher than average price of previous purchases. This sale made a profit of USD 143 The average price that the ETF previously sold OABI share for is USD 2.7312 which is higher than the selling price of USD 1.94 on 2025-12-23. |
| AVIR - Atea Pharmaceuticals Inc | SELL | -1,740 @ USD 3.43001 | USD -5,968 | The ETF sold 1740 shares of AVIR on 2025-12-23. The shares were previously bought for an average price of USD 3.23853. The Atea Pharmaceuticals Inc shares were sold for 5.9% higher than average price of previous purchases. This sale made a profit of USD 333 The average price that the ETF previously sold AVIR share for is USD 3.13115 so the ETF has sold 1740 shares on 2025-12-23 at a higher price than the previous selling average. |
| AUTL - Autolus Therapeutics Ltd | SELL | -3,684 @ USD 1.64 | USD -6,042 | The ETF sold 3684 shares of AUTL on 2025-12-23. The shares were previously bought for an average price of USD 1.72671. The Autolus Therapeutics Ltd shares were sold for -5.0% lower than average price of previous purchases. This resulted in an overall loss of USD 319 The average price that the ETF previously sold AUTL share for is USD 1.88392 which is higher than the selling price of USD 1.64 on 2025-12-23. |
| ACRS - Aclaris Therapeutics Inc | SELL | -2,100 @ USD 2.9 | USD -6,090 | The ETF sold 2100 shares of ACRS on 2025-12-23. The shares were previously bought for an average price of USD . The Aclaris Therapeutics Inc shares were sold for 0.0% than average price of previous purchases. The average price that the ETF previously sold ACRS share for is USD 2.99707 which is higher than the selling price of USD 2.9 on 2025-12-23. |
| ALLO - Allogene Therapeutics Inc | SELL | -4,524 @ USD 1.36 | USD -6,153 | The ETF sold 4524 shares of ALLO on 2025-12-23. The shares were previously bought for an average price of USD 1.34961. The Allogene Therapeutics Inc shares were sold for 0.8% higher than average price of previous purchases. This sale made a profit of USD 47 The average price that the ETF previously sold ALLO share for is USD 1.8242 which is higher than the selling price of USD 1.36 on 2025-12-23. |
| ACIU - AC Immune Ltd | SELL | -2,064 @ USD 3.15 | USD -6,502 | The ETF sold 2064 shares of ACIU on 2025-12-23. The shares were previously bought for an average price of USD 2.58078. The AC Immune Ltd shares were sold for 22.1% higher than average price of previous purchases. This sale made a profit of USD 1,175 The average price that the ETF previously sold ACIU share for is USD 2.40544 so the ETF has sold 2064 shares on 2025-12-23 at a higher price than the previous selling average. |
| AVXL - Anavex Life Sciences Corp | SELL | -1,776 @ USD 3.73 | USD -6,624 | The ETF sold 1776 shares of AVXL on 2025-12-23. The shares were previously bought for an average price of USD 8.00044. The Anavex Life Sciences Corp shares were sold for -53.4% lower than average price of previous purchases. This resulted in an overall loss of USD 7,584 The average price that the ETF previously sold AVXL share for is USD 9.12554 which is higher than the selling price of USD 3.73 on 2025-12-23. |
| BCYC - Bicycle Therapeutics Ltd | SELL | -972 @ USD 6.94001 | USD -6,746 | The ETF sold 972 shares of BCYC on 2025-12-23. The shares were previously bought for an average price of USD 8.15311. The Bicycle Therapeutics Ltd shares were sold for -14.9% lower than average price of previous purchases. This resulted in an overall loss of USD 1,179 The average price that the ETF previously sold BCYC share for is USD 10.417 which is higher than the selling price of USD 6.94001 on 2025-12-23. |
| RCKT - Rocket Pharmaceuticals Inc | SELL | -2,196 @ USD 3.44999 | USD -7,576 | The ETF sold 2196 shares of RCKT on 2025-12-23. The shares were previously bought for an average price of USD 4.68034. The Rocket Pharmaceuticals Inc shares were sold for -26.3% lower than average price of previous purchases. This resulted in an overall loss of USD 2,702 The average price that the ETF previously sold RCKT share for is USD 8.42152 which is higher than the selling price of USD 3.44999 on 2025-12-23. |
| TRDA - Entrada Therapeutics Inc | SELL | -720 @ USD 10.63 | USD -7,654 | The ETF sold 720 shares of TRDA on 2025-12-23. The shares were previously bought for an average price of USD 8.26934. The Entrada Therapeutics Inc shares were sold for 28.5% higher than average price of previous purchases. This sale made a profit of USD 1,700 The average price that the ETF previously sold TRDA share for is USD 9.92314 so the ETF has sold 720 shares on 2025-12-23 at a higher price than the previous selling average. |
| VNDA - Vanda Pharmaceuticals Inc | SELL | -1,128 @ USD 6.84 | USD -7,716 | The ETF sold 1128 shares of VNDA on 2025-12-23. The shares were previously bought for an average price of USD 4.93435. The Vanda Pharmaceuticals Inc shares were sold for 38.6% higher than average price of previous purchases. This sale made a profit of USD 2,150 The average price that the ETF previously sold VNDA share for is USD 5.44946 so the ETF has sold 1128 shares on 2025-12-23 at a higher price than the previous selling average. |
| ALT - Altitude Group Plc | SELL | -2,004 @ USD 4 | USD -8,016 | The ETF sold 2004 shares of ALT on 2025-12-23. The shares were previously bought for an average price of USD 4.91477. The Altitude Group Plc shares were sold for -18.6% lower than average price of previous purchases. This resulted in an overall loss of USD 1,833 The average price that the ETF previously sold ALT share for is USD 4.80782 which is higher than the selling price of USD 4 on 2025-12-23. |
| FDMT - 4D Molecular Therapeutics Inc | SELL | -1,020 @ USD 7.89999 | USD -8,058 | The ETF sold 1020 shares of FDMT on 2025-12-23. The shares were previously bought for an average price of USD 7.85517. The 4D Molecular Therapeutics Inc shares were sold for 0.6% higher than average price of previous purchases. This sale made a profit of USD 46 The average price that the ETF previously sold FDMT share for is USD 5.63736 so the ETF has sold 1020 shares on 2025-12-23 at a higher price than the previous selling average. |
| EOLS - Evolus Inc | SELL | -1,236 @ USD 6.81001 | USD -8,417 | The ETF sold 1236 shares of EOLS on 2025-12-23. The shares were previously bought for an average price of USD 8.55984. The Evolus Inc shares were sold for -20.4% lower than average price of previous purchases. This resulted in an overall loss of USD 2,163 The average price that the ETF previously sold EOLS share for is USD 9.41617 which is higher than the selling price of USD 6.81001 on 2025-12-23. |
| GLPG - Galapagos NV ADR | SELL | -264 @ USD 32.94 | USD -8,696 | The ETF sold 264 shares of GLPG on 2025-12-23. The shares were previously bought for an average price of USD 29.6758. The Galapagos NV ADR shares were sold for 11.0% higher than average price of previous purchases. This sale made a profit of USD 862 The average price that the ETF previously sold GLPG share for is USD 28.2424 so the ETF has sold 264 shares on 2025-12-23 at a higher price than the previous selling average. |
| GLPG - Galapagos N.V. | SELL | -264 @ USD 32.94 | USD -8,696 | The ETF sold 264 shares of GLPG on 2025-12-23. The shares were previously bought for an average price of USD 29.6758. The Galapagos N.V. shares were sold for 11.0% higher than average price of previous purchases. This sale made a profit of USD 862 The average price that the ETF previously sold GLPG share for is USD 28.2424 so the ETF has sold 264 shares on 2025-12-23 at a higher price than the previous selling average. |
| SIGA - SIGA Technologies Inc | SELL | -1,428 @ USD 6.23 | USD -8,896 | The ETF sold 1428 shares of SIGA on 2025-12-23. The shares were previously bought for an average price of USD 6.62905. The SIGA Technologies Inc shares were sold for -6.0% lower than average price of previous purchases. This resulted in an overall loss of USD 570 The average price that the ETF previously sold SIGA share for is USD 6.05145 so the ETF has sold 1428 shares on 2025-12-23 at a higher price than the previous selling average. |
| MRVI - Maravai Lifesciences Holdings Inc | SELL | -2,772 @ USD 3.29 | USD -9,120 | The ETF sold 2772 shares of MRVI on 2025-12-23. The shares were previously bought for an average price of USD 2.9452. The Maravai Lifesciences Holdings Inc shares were sold for 11.7% higher than average price of previous purchases. This sale made a profit of USD 956 The average price that the ETF previously sold MRVI share for is USD 3.62987 which is higher than the selling price of USD 3.29 on 2025-12-23. |
| IRWD - Ironwood Pharmaceuticals Inc | SELL | -3,108 @ USD 3.21 | USD -9,977 | The ETF sold 3108 shares of IRWD on 2025-12-23. The shares were previously bought for an average price of USD 2.38219. The Ironwood Pharmaceuticals Inc shares were sold for 34.7% higher than average price of previous purchases. This sale made a profit of USD 2,573 The average price that the ETF previously sold IRWD share for is USD 2.89499 so the ETF has sold 3108 shares on 2025-12-23 at a higher price than the previous selling average. |
| PRTA - Prothena Corporation plc | SELL | -1,104 @ USD 9.49 | USD -10,477 | The ETF sold 1104 shares of PRTA on 2025-12-23. The shares were previously bought for an average price of USD 9.51984. The Prothena Corporation plc shares were sold for -0.3% lower than average price of previous purchases. This resulted in an overall loss of USD 33 The average price that the ETF previously sold PRTA share for is USD 12.3338 which is higher than the selling price of USD 9.49 on 2025-12-23. |
| PACB - Pacific Biosciences of California | SELL | -5,772 @ USD 1.82 | USD -10,505 | The ETF sold 5772 shares of PACB on 2025-12-23. The shares were previously bought for an average price of USD 1.72925. The Pacific Biosciences of California shares were sold for 5.2% higher than average price of previous purchases. This sale made a profit of USD 524 The average price that the ETF previously sold PACB share for is USD 1.65227 so the ETF has sold 5772 shares on 2025-12-23 at a higher price than the previous selling average. |
| CGEM - Cullinan Oncology LLC | SELL | -1,104 @ USD 10 | USD -11,040 | The ETF sold 1104 shares of CGEM on 2025-12-23. The shares were previously bought for an average price of USD 8.59538. The Cullinan Oncology LLC shares were sold for 16.3% higher than average price of previous purchases. This sale made a profit of USD 1,551 The average price that the ETF previously sold CGEM share for is USD 10.0239 which is higher than the selling price of USD 10 on 2025-12-23. |
| MGTX - MeiraGTx Holdings PLC | SELL | -1,464 @ USD 7.87001 | USD -11,522 | The ETF sold 1464 shares of MGTX on 2025-12-23. The shares were previously bought for an average price of USD 7.41976. The MeiraGTx Holdings PLC shares were sold for 6.1% higher than average price of previous purchases. This sale made a profit of USD 659 The average price that the ETF previously sold MGTX share for is USD 7.02058 so the ETF has sold 1464 shares on 2025-12-23 at a higher price than the previous selling average. |
| FULC - Fulcrum Therapeutics Inc | SELL | -1,020 @ USD 11.79 | USD -12,026 | The ETF sold 1020 shares of FULC on 2025-12-23. The shares were previously bought for an average price of USD . The Fulcrum Therapeutics Inc shares were sold for 0.0% than average price of previous purchases. The average price that the ETF previously sold FULC share for is USD 3.0853 so the ETF has sold 1020 shares on 2025-12-23 at a higher price than the previous selling average. |
| VTYX - Ventyx Biosciences Inc | SELL | -1,356 @ USD 9.07 | USD -12,299 | The ETF sold 1356 shares of VTYX on 2025-12-23. The shares were previously bought for an average price of USD . The Ventyx Biosciences Inc shares were sold for 0.0% than average price of previous purchases. The average price that the ETF previously sold VTYX share for is USD 1.83177 so the ETF has sold 1356 shares on 2025-12-23 at a higher price than the previous selling average. |
| KROS - Keros Therapeutics Inc | SELL | -576 @ USD 21.38 | USD -12,315 | The ETF sold 576 shares of KROS on 2025-12-23. The shares were previously bought for an average price of USD 15.8802. The Keros Therapeutics Inc shares were sold for 34.6% higher than average price of previous purchases. This sale made a profit of USD 3,168 The average price that the ETF previously sold KROS share for is USD 20.7135 so the ETF has sold 576 shares on 2025-12-23 at a higher price than the previous selling average. |
| ZLAB - Zai Lab Ltd | SELL | -744 @ USD 17.48 | USD -13,005 | The ETF sold 744 shares of ZLAB on 2025-12-23. The shares were previously bought for an average price of USD 30.9501. The Zai Lab Ltd shares were sold for -43.5% lower than average price of previous purchases. This resulted in an overall loss of USD 10,022 The average price that the ETF previously sold ZLAB share for is USD 24.5387 which is higher than the selling price of USD 17.48 on 2025-12-23. |
| PRME - Prime Medicine, Inc. Common Stock | SELL | -3,528 @ USD 3.69 | USD -13,018 | The ETF sold 3528 shares of PRME on 2025-12-23. The shares were previously bought for an average price of USD 3.872. The Prime Medicine, Inc. Common Stock shares were sold for -4.7% lower than average price of previous purchases. This resulted in an overall loss of USD 642 The average price that the ETF previously sold PRME share for is USD 2.84336 so the ETF has sold 3528 shares on 2025-12-23 at a higher price than the previous selling average. |
| RGNX - Regenxbio Inc | SELL | -960 @ USD 14.35 | USD -13,776 | The ETF sold 960 shares of RGNX on 2025-12-23. The shares were previously bought for an average price of USD 10.0677. The Regenxbio Inc shares were sold for 42.5% higher than average price of previous purchases. This sale made a profit of USD 4,111 The average price that the ETF previously sold RGNX share for is USD 9.76496 so the ETF has sold 960 shares on 2025-12-23 at a higher price than the previous selling average. |
| LYEL - Lyell Immunopharma Inc | SELL | -384 @ USD 37.33 | USD -14,335 | The ETF sold 384 shares of LYEL on 2025-12-23. The shares were previously bought for an average price of USD 7.12732. The Lyell Immunopharma Inc shares were sold for 423.8% higher than average price of previous purchases. This sale made a profit of USD 11,598 The average price that the ETF previously sold LYEL share for is USD 6.6753 so the ETF has sold 384 shares on 2025-12-23 at a higher price than the previous selling average. |
| REPL - Replimune Group Inc | SELL | -1,476 @ USD 9.72 | USD -14,347 | The ETF sold 1476 shares of REPL on 2025-12-23. The shares were previously bought for an average price of USD 9.21424. The Replimune Group Inc shares were sold for 5.5% higher than average price of previous purchases. This sale made a profit of USD 747 The average price that the ETF previously sold REPL share for is USD 10.0821 which is higher than the selling price of USD 9.72 on 2025-12-23. |
| ARVN - Arvinas Inc | SELL | -1,212 @ USD 12.18 | USD -14,762 | The ETF sold 1212 shares of ARVN on 2025-12-23. The shares were previously bought for an average price of USD 9.97558. The Arvinas Inc shares were sold for 22.1% higher than average price of previous purchases. This sale made a profit of USD 2,672 The average price that the ETF previously sold ARVN share for is USD 12.8131 which is higher than the selling price of USD 12.18 on 2025-12-23. |
| PAHC - Phibro Animal Health Corporation | SELL | -396 @ USD 37.39 | USD -14,806 | The ETF sold 396 shares of PAHC on 2025-12-23. The shares were previously bought for an average price of USD 31.5346. The Phibro Animal Health Corporation shares were sold for 18.6% higher than average price of previous purchases. This sale made a profit of USD 2,319 The average price that the ETF previously sold PAHC share for is USD 24.1119 so the ETF has sold 396 shares on 2025-12-23 at a higher price than the previous selling average. |
| ORIC - Oric Pharmaceuticals Inc | SELL | -1,800 @ USD 8.27 | USD -14,886 | The ETF sold 1800 shares of ORIC on 2025-12-23. The shares were previously bought for an average price of USD 10.7122. The Oric Pharmaceuticals Inc shares were sold for -22.8% lower than average price of previous purchases. This resulted in an overall loss of USD 4,396 The average price that the ETF previously sold ORIC share for is USD 8.18863 so the ETF has sold 1800 shares on 2025-12-23 at a higher price than the previous selling average. |
| KALV - Kalvista Pharmaceuticals Inc | SELL | -948 @ USD 15.75 | USD -14,931 | The ETF sold 948 shares of KALV on 2025-12-23. The shares were previously bought for an average price of USD 13.5388. The Kalvista Pharmaceuticals Inc shares were sold for 16.3% higher than average price of previous purchases. This sale made a profit of USD 2,096 The average price that the ETF previously sold KALV share for is USD 13.104 so the ETF has sold 948 shares on 2025-12-23 at a higher price than the previous selling average. |
| VIR - Vir Biotechnology Inc | SELL | -2,568 @ USD 5.99 | USD -15,382 | The ETF sold 2568 shares of VIR on 2025-12-23. The shares were previously bought for an average price of USD 5.93668. The Vir Biotechnology Inc shares were sold for 0.9% higher than average price of previous purchases. This sale made a profit of USD 137 The average price that the ETF previously sold VIR share for is USD 6.48008 which is higher than the selling price of USD 5.99 on 2025-12-23. |
| VIR - Vidrala S.A | SELL | -2,568 @ USD 5.99 | USD -15,382 | The ETF sold 2568 shares of VIR on 2025-12-23. The shares were previously bought for an average price of USD 5.93668. The Vidrala S.A shares were sold for 0.9% higher than average price of previous purchases. This sale made a profit of USD 137 The average price that the ETF previously sold VIR share for is USD 6.48008 which is higher than the selling price of USD 5.99 on 2025-12-23. |
| GERN - Geron Corporation | SELL | -11,832 @ USD 1.33 | USD -15,737 | The ETF sold 11832 shares of GERN on 2025-12-23. The shares were previously bought for an average price of USD 1.44548. The Geron Corporation shares were sold for -8.0% lower than average price of previous purchases. This resulted in an overall loss of USD 1,366 The average price that the ETF previously sold GERN share for is USD 2.1384 which is higher than the selling price of USD 1.33 on 2025-12-23. |
| JANX - Janux Therapeutics Inc | SELL | -1,116 @ USD 14.12 | USD -15,758 | The ETF sold 1116 shares of JANX on 2025-12-23. The shares were previously bought for an average price of USD 26.2738. The Janux Therapeutics Inc shares were sold for -46.3% lower than average price of previous purchases. This resulted in an overall loss of USD 13,564 The average price that the ETF previously sold JANX share for is USD 31.7186 which is higher than the selling price of USD 14.12 on 2025-12-23. |
| ABUS - Arbutus Biopharma Corp | SELL | -3,636 @ USD 4.68 | USD -17,016 | The ETF sold 3636 shares of ABUS on 2025-12-23. The shares were previously bought for an average price of USD 3.8558. The Arbutus Biopharma Corp shares were sold for 21.4% higher than average price of previous purchases. This sale made a profit of USD 2,997 The average price that the ETF previously sold ABUS share for is USD 3.65403 so the ETF has sold 3636 shares on 2025-12-23 at a higher price than the previous selling average. |
| TBPH - Theravance Biopharma Inc | SELL | -936 @ USD 18.57 | USD -17,382 | The ETF sold 936 shares of TBPH on 2025-12-23. The shares were previously bought for an average price of USD 13.6055. The Theravance Biopharma Inc shares were sold for 36.5% higher than average price of previous purchases. This sale made a profit of USD 4,647 The average price that the ETF previously sold TBPH share for is USD 12.7629 so the ETF has sold 936 shares on 2025-12-23 at a higher price than the previous selling average. |
| KURA - Kura Oncology Inc | SELL | -1,644 @ USD 10.79 | USD -17,739 | The ETF sold 1644 shares of KURA on 2025-12-23. The shares were previously bought for an average price of USD 8.32957. The Kura Oncology Inc shares were sold for 29.5% higher than average price of previous purchases. This sale made a profit of USD 4,045 The average price that the ETF previously sold KURA share for is USD 9.26857 so the ETF has sold 1644 shares on 2025-12-23 at a higher price than the previous selling average. |
| ERAS - Erasca Inc | SELL | -5,364 @ USD 3.39 | USD -18,184 | The ETF sold 5364 shares of ERAS on 2025-12-23. The shares were previously bought for an average price of USD 2.03843. The Erasca Inc shares were sold for 66.3% higher than average price of previous purchases. This sale made a profit of USD 7,250 The average price that the ETF previously sold ERAS share for is USD 2.55371 so the ETF has sold 5364 shares on 2025-12-23 at a higher price than the previous selling average. |
| ELVN - Enliven Therapeutics Inc. | SELL | -1,104 @ USD 16.53 | USD -18,249 | The ETF sold 1104 shares of ELVN on 2025-12-23. The shares were previously bought for an average price of USD 20.9173. The Enliven Therapeutics Inc. shares were sold for -21.0% lower than average price of previous purchases. This resulted in an overall loss of USD 4,844 The average price that the ETF previously sold ELVN share for is USD 20.0305 which is higher than the selling price of USD 16.53 on 2025-12-23. |
| DAWN - Day One Biopharmaceuticals Inc | SELL | -1,896 @ USD 9.62999 | USD -18,258 | The ETF sold 1896 shares of DAWN on 2025-12-23. The shares were previously bought for an average price of USD 7.73772. The Day One Biopharmaceuticals Inc shares were sold for 24.5% higher than average price of previous purchases. This sale made a profit of USD 3,588 The average price that the ETF previously sold DAWN share for is USD 9.73432 which is higher than the selling price of USD 9.62999 on 2025-12-23. |
| RAPT - RAPT Therapeutics Inc | SELL | -516 @ USD 35.4 | USD -18,266 | The ETF sold 516 shares of RAPT on 2025-12-23. The shares were previously bought for an average price of USD . The RAPT Therapeutics Inc shares were sold for 0.0% than average price of previous purchases. The average price that the ETF previously sold RAPT share for is USD 1.23736 so the ETF has sold 516 shares on 2025-12-23 at a higher price than the previous selling average. |
| IOVA - Iovance Biotherapeutics Inc | SELL | -7,116 @ USD 2.82 | USD -20,067 | The ETF sold 7116 shares of IOVA on 2025-12-23. The shares were previously bought for an average price of USD 2.39299. The Iovance Biotherapeutics Inc shares were sold for 17.8% higher than average price of previous purchases. This sale made a profit of USD 3,039 The average price that the ETF previously sold IOVA share for is USD 4.87442 which is higher than the selling price of USD 2.82 on 2025-12-23. |
| NTLA - Intellia Therapeutics Inc | SELL | -2,172 @ USD 9.42 | USD -20,460 | The ETF sold 2172 shares of NTLA on 2025-12-23. The shares were previously bought for an average price of USD 11.4501. The Intellia Therapeutics Inc shares were sold for -17.7% lower than average price of previous purchases. This resulted in an overall loss of USD 4,409 The average price that the ETF previously sold NTLA share for is USD 11.0306 which is higher than the selling price of USD 9.42 on 2025-12-23. |
| URGN - UroGen Pharma Ltd | SELL | -876 @ USD 23.4 | USD -20,498 | The ETF sold 876 shares of URGN on 2025-12-23. The shares were previously bought for an average price of USD 17.004. The UroGen Pharma Ltd shares were sold for 37.6% higher than average price of previous purchases. This sale made a profit of USD 5,603 The average price that the ETF previously sold URGN share for is USD 14.9146 so the ETF has sold 876 shares on 2025-12-23 at a higher price than the previous selling average. |
| SPRY - Silverback Therapeutics Inc | SELL | -1,860 @ USD 11.03 | USD -20,516 | The ETF sold 1860 shares of SPRY on 2025-12-23. The shares were previously bought for an average price of USD 12.3064. The Silverback Therapeutics Inc shares were sold for -10.4% lower than average price of previous purchases. This resulted in an overall loss of USD 2,374 The average price that the ETF previously sold SPRY share for is USD 11.7256 which is higher than the selling price of USD 11.03 on 2025-12-23. |
| PCRX - Pacira BioSciences, Inc. | SELL | -804 @ USD 25.74 | USD -20,695 | The ETF sold 804 shares of PCRX on 2025-12-23. The shares were previously bought for an average price of USD 23.9147. The Pacira BioSciences, Inc. shares were sold for 7.6% higher than average price of previous purchases. This sale made a profit of USD 1,468 The average price that the ETF previously sold PCRX share for is USD 22.5983 so the ETF has sold 804 shares on 2025-12-23 at a higher price than the previous selling average. |
| ABCL - Abcellera Biologics Inc | SELL | -5,616 @ USD 3.69 | USD -20,723 | The ETF sold 5616 shares of ABCL on 2025-12-23. The shares were previously bought for an average price of USD 3.82652. The Abcellera Biologics Inc shares were sold for -3.6% lower than average price of previous purchases. This resulted in an overall loss of USD 767 The average price that the ETF previously sold ABCL share for is USD 3.02387 so the ETF has sold 5616 shares on 2025-12-23 at a higher price than the previous selling average. |
| XNCR - Xencor Inc | SELL | -1,344 @ USD 15.47 | USD -20,792 | The ETF sold 1344 shares of XNCR on 2025-12-23. The shares were previously bought for an average price of USD 12.6245. The Xencor Inc shares were sold for 22.5% higher than average price of previous purchases. This sale made a profit of USD 3,824 The average price that the ETF previously sold XNCR share for is USD 14.5783 so the ETF has sold 1344 shares on 2025-12-23 at a higher price than the previous selling average. |
| NVAX - Novavax Inc | SELL | -3,060 @ USD 6.8 | USD -20,808 | The ETF sold 3060 shares of NVAX on 2025-12-23. The shares were previously bought for an average price of USD 7.2182. The Novavax Inc shares were sold for -5.8% lower than average price of previous purchases. This resulted in an overall loss of USD 1,280 The average price that the ETF previously sold NVAX share for is USD 7.2861 which is higher than the selling price of USD 6.8 on 2025-12-23. |
| NVAX - Hana Microelectronics Public Company Limited | SELL | -3,060 @ USD 6.8 | USD -20,808 | The ETF sold 3060 shares of NVAX on 2025-12-23. The shares were previously bought for an average price of USD 7.2182. The Hana Microelectronics Public Company Limited shares were sold for -5.8% lower than average price of previous purchases. This resulted in an overall loss of USD 1,280 The average price that the ETF previously sold NVAX share for is USD 7.2861 which is higher than the selling price of USD 6.8 on 2025-12-23. |
| GRFS - Grifols SA ADR | SELL | -2,304 @ USD 9.11 | USD -20,989 | The ETF sold 2304 shares of GRFS on 2025-12-23. The shares were previously bought for an average price of USD 9.17332. The Grifols SA ADR shares were sold for -0.7% lower than average price of previous purchases. This resulted in an overall loss of USD 146 The average price that the ETF previously sold GRFS share for is USD 8.25966 so the ETF has sold 2304 shares on 2025-12-23 at a higher price than the previous selling average. |
| TNGX - Tango Therapeutics Inc | SELL | -2,544 @ USD 8.53 | USD -21,700 | The ETF sold 2544 shares of TNGX on 2025-12-23. The shares were previously bought for an average price of USD 7.61917. The Tango Therapeutics Inc shares were sold for 12.0% higher than average price of previous purchases. This sale made a profit of USD 2,317 The average price that the ETF previously sold TNGX share for is USD 3.84765 so the ETF has sold 2544 shares on 2025-12-23 at a higher price than the previous selling average. |
| CSTL - Castle Biosciences Inc | SELL | -540 @ USD 40.2 | USD -21,708 | The ETF sold 540 shares of CSTL on 2025-12-23. The shares were previously bought for an average price of USD 26.4684. The Castle Biosciences Inc shares were sold for 51.9% higher than average price of previous purchases. This sale made a profit of USD 7,415 The average price that the ETF previously sold CSTL share for is USD 27.2629 so the ETF has sold 540 shares on 2025-12-23 at a higher price than the previous selling average. |
| SANA - Sana Biotechnology Inc | SELL | -4,992 @ USD 4.53 | USD -22,614 | The ETF sold 4992 shares of SANA on 2025-12-23. The shares were previously bought for an average price of USD 3.48775. The Sana Biotechnology Inc shares were sold for 29.9% higher than average price of previous purchases. This sale made a profit of USD 5,203 The average price that the ETF previously sold SANA share for is USD 2.82531 so the ETF has sold 4992 shares on 2025-12-23 at a higher price than the previous selling average. |
| XERS - Xeris Pharmaceuticals Inc | SELL | -3,132 @ USD 7.28 | USD -22,801 | The ETF sold 3132 shares of XERS on 2025-12-23. The shares were previously bought for an average price of USD 6.25114. The Xeris Pharmaceuticals Inc shares were sold for 16.5% higher than average price of previous purchases. This sale made a profit of USD 3,222 The average price that the ETF previously sold XERS share for is USD 4.98421 so the ETF has sold 3132 shares on 2025-12-23 at a higher price than the previous selling average. |
| AMPH - Amphastar P | SELL | -864 @ USD 26.45 | USD -22,853 | The ETF sold 864 shares of AMPH on 2025-12-23. The shares were previously bought for an average price of USD 25.9418. The Amphastar P shares were sold for 2.0% higher than average price of previous purchases. This sale made a profit of USD 439 The average price that the ETF previously sold AMPH share for is USD 30.972 which is higher than the selling price of USD 26.45 on 2025-12-23. |
| PHAT - Phathom Pharmaceuticals Inc | SELL | -1,332 @ USD 17.25 | USD -22,977 | The ETF sold 1332 shares of PHAT on 2025-12-23. The shares were previously bought for an average price of USD 10.5986. The Phathom Pharmaceuticals Inc shares were sold for 62.8% higher than average price of previous purchases. This sale made a profit of USD 8,860 The average price that the ETF previously sold PHAT share for is USD 10.1847 so the ETF has sold 1332 shares on 2025-12-23 at a higher price than the previous selling average. |
| DVAX - Dynavax Technologies Corporation | SELL | -2,208 @ USD 11.13 | USD -24,575 | The ETF sold 2208 shares of DVAX on 2025-12-23. The shares were previously bought for an average price of USD 10.6292. The Dynavax Technologies Corporation shares were sold for 4.7% higher than average price of previous purchases. This sale made a profit of USD 1,106 The average price that the ETF previously sold DVAX share for is USD 11.9933 which is higher than the selling price of USD 11.13 on 2025-12-23. |
| SVRA - Savara Inc | SELL | -3,828 @ USD 6.44 | USD -24,652 | The ETF sold 3828 shares of SVRA on 2025-12-23. The shares were previously bought for an average price of USD 4.24735. The Savara Inc shares were sold for 51.6% higher than average price of previous purchases. This sale made a profit of USD 8,393 The average price that the ETF previously sold SVRA share for is USD 3.13549 so the ETF has sold 3828 shares on 2025-12-23 at a higher price than the previous selling average. |
| AMLX - Amylyx Pharmaceuticals Inc | SELL | -2,064 @ USD 12.31 | USD -25,408 | The ETF sold 2064 shares of AMLX on 2025-12-23. The shares were previously bought for an average price of USD 9.1744. The Amylyx Pharmaceuticals Inc shares were sold for 34.2% higher than average price of previous purchases. This sale made a profit of USD 6,472 The average price that the ETF previously sold AMLX share for is USD 6.34558 so the ETF has sold 2064 shares on 2025-12-23 at a higher price than the previous selling average. |
| ANAB - AnaptysBio Inc | SELL | -516 @ USD 50.04 | USD -25,821 | The ETF sold 516 shares of ANAB on 2025-12-23. The shares were previously bought for an average price of USD 28.5875. The AnaptysBio Inc shares were sold for 75.0% higher than average price of previous purchases. This sale made a profit of USD 11,069 The average price that the ETF previously sold ANAB share for is USD 25.1169 so the ETF has sold 516 shares on 2025-12-23 at a higher price than the previous selling average. |
| MNMD - Mind Medicine Inc | SELL | -1,848 @ USD 14.02 | USD -25,909 | The ETF sold 1848 shares of MNMD on 2025-12-23. The shares were previously bought for an average price of USD 10.4744. The Mind Medicine Inc shares were sold for 33.9% higher than average price of previous purchases. This sale made a profit of USD 6,552 The average price that the ETF previously sold MNMD share for is USD 7.66779 so the ETF has sold 1848 shares on 2025-12-23 at a higher price than the previous selling average. |
| ARDX - Ardelyx Inc | SELL | -4,572 @ USD 5.8 | USD -26,518 | The ETF sold 4572 shares of ARDX on 2025-12-23. The shares were previously bought for an average price of USD 4.93508. The Ardelyx Inc shares were sold for 17.5% higher than average price of previous purchases. This sale made a profit of USD 3,954 The average price that the ETF previously sold ARDX share for is USD 5.17828 so the ETF has sold 4572 shares on 2025-12-23 at a higher price than the previous selling average. |
| AGIO - Agios Pharm | SELL | -1,092 @ USD 24.59 | USD -26,852 | The ETF sold 1092 shares of AGIO on 2025-12-23. The shares were previously bought for an average price of USD 33.837. The Agios Pharm shares were sold for -27.3% lower than average price of previous purchases. This resulted in an overall loss of USD 10,098 The average price that the ETF previously sold AGIO share for is USD 32.1781 which is higher than the selling price of USD 24.59 on 2025-12-23. |
| PGEN - Precigen Inc | SELL | -6,660 @ USD 4.07 | USD -27,106 | The ETF sold 6660 shares of PGEN on 2025-12-23. The shares were previously bought for an average price of USD 2.99077. The Precigen Inc shares were sold for 36.1% higher than average price of previous purchases. This sale made a profit of USD 7,188 The average price that the ETF previously sold PGEN share for is USD 1.81069 so the ETF has sold 6660 shares on 2025-12-23 at a higher price than the previous selling average. |
| RLAY - Relay Therapeutics Inc | SELL | -3,264 @ USD 8.31 | USD -27,124 | The ETF sold 3264 shares of RLAY on 2025-12-23. The shares were previously bought for an average price of USD 4.92682. The Relay Therapeutics Inc shares were sold for 68.7% higher than average price of previous purchases. This sale made a profit of USD 11,043 The average price that the ETF previously sold RLAY share for is USD 5.14279 so the ETF has sold 3264 shares on 2025-12-23 at a higher price than the previous selling average. |
| INVA - Innoviva Inc | SELL | -1,404 @ USD 19.51 | USD -27,392 | The ETF sold 1404 shares of INVA on 2025-12-23. The shares were previously bought for an average price of USD 19.6892. The Innoviva Inc shares were sold for -0.9% lower than average price of previous purchases. This resulted in an overall loss of USD 252 The average price that the ETF previously sold INVA share for is USD 18.1345 so the ETF has sold 1404 shares on 2025-12-23 at a higher price than the previous selling average. |
| NVCR - Novocure Ltd | SELL | -2,100 @ USD 13.27 | USD -27,867 | The ETF sold 2100 shares of NVCR on 2025-12-23. The shares were previously bought for an average price of USD 15.442. The Novocure Ltd shares were sold for -14.1% lower than average price of previous purchases. This resulted in an overall loss of USD 4,561 The average price that the ETF previously sold NVCR share for is USD 18.9142 which is higher than the selling price of USD 13.27 on 2025-12-23. |
| QURE - Uniqure NV | SELL | -1,164 @ USD 24.18 | USD -28,146 | The ETF sold 1164 shares of QURE on 2025-12-23. The shares were previously bought for an average price of USD 23.6727. The Uniqure NV shares were sold for 2.1% higher than average price of previous purchases. This sale made a profit of USD 590 The average price that the ETF previously sold QURE share for is USD 15.3734 so the ETF has sold 1164 shares on 2025-12-23 at a higher price than the previous selling average. |
| COLL - Collegium Pharmaceutical Inc | SELL | -588 @ USD 48.85 | USD -28,724 | The ETF sold 588 shares of COLL on 2025-12-23. The shares were previously bought for an average price of USD 35.7679. The Collegium Pharmaceutical Inc shares were sold for 36.6% higher than average price of previous purchases. This sale made a profit of USD 7,692 The average price that the ETF previously sold COLL share for is USD 33.6234 so the ETF has sold 588 shares on 2025-12-23 at a higher price than the previous selling average. |
| TSHA - Taysha Gene Therapies Inc | SELL | -5,148 @ USD 5.71 | USD -29,395 | The ETF sold 5148 shares of TSHA on 2025-12-23. The shares were previously bought for an average price of USD 3.28075. The Taysha Gene Therapies Inc shares were sold for 74.0% higher than average price of previous purchases. This sale made a profit of USD 12,506 The average price that the ETF previously sold TSHA share for is USD 2.86672 so the ETF has sold 5148 shares on 2025-12-23 at a higher price than the previous selling average. |
| IMCR - Immunocore Holdings Ltd | SELL | -816 @ USD 36.19 | USD -29,531 | The ETF sold 816 shares of IMCR on 2025-12-23. The shares were previously bought for an average price of USD 34.3307. The Immunocore Holdings Ltd shares were sold for 5.4% higher than average price of previous purchases. This sale made a profit of USD 1,517 The average price that the ETF previously sold IMCR share for is USD 30.6295 so the ETF has sold 816 shares on 2025-12-23 at a higher price than the previous selling average. |
| BCRX - BioCryst Pharmaceuticals Inc | SELL | -3,960 @ USD 7.53 | USD -29,819 | The ETF sold 3960 shares of BCRX on 2025-12-23. The shares were previously bought for an average price of USD 8.03325. The BioCryst Pharmaceuticals Inc shares were sold for -6.3% lower than average price of previous purchases. This resulted in an overall loss of USD 1,993 The average price that the ETF previously sold BCRX share for is USD 7.46526 so the ETF has sold 3960 shares on 2025-12-23 at a higher price than the previous selling average. |
| FTRE - Fortrea Holdings Inc. | SELL | -1,728 @ USD 17.91 | USD -30,948 | The ETF sold 1728 shares of FTRE on 2025-12-23. The shares were previously bought for an average price of USD 8.51315. The Fortrea Holdings Inc. shares were sold for 110.4% higher than average price of previous purchases. This sale made a profit of USD 16,238 The average price that the ETF previously sold FTRE share for is USD 14.9 so the ETF has sold 1728 shares on 2025-12-23 at a higher price than the previous selling average. |
| PHVS - Pharvaris BV | SELL | -1,209 @ USD 25.85 | USD -31,253 | The ETF sold 1209 shares of PHVS on 2025-12-23. The shares were previously bought for an average price of USD . The Pharvaris BV shares were sold for 0.0% than average price of previous purchases. The average price that the ETF previously sold PHVS share for is USD so the ETF has sold 1209 shares on 2025-12-23 at a higher price than the previous selling average. |
| ANIP - ANI Pharmaceuticals Inc | SELL | -420 @ USD 80.73 | USD -33,907 | The ETF sold 420 shares of ANIP on 2025-12-23. The shares were previously bought for an average price of USD 75.802. The ANI Pharmaceuticals Inc shares were sold for 6.5% higher than average price of previous purchases. This sale made a profit of USD 2,070 The average price that the ETF previously sold ANIP share for is USD 66.287 so the ETF has sold 420 shares on 2025-12-23 at a higher price than the previous selling average. |
| STOK - Stoke Therapeutics Inc | SELL | -1,068 @ USD 31.86 | USD -34,026 | The ETF sold 1068 shares of STOK on 2025-12-23. The shares were previously bought for an average price of USD 19.8446. The Stoke Therapeutics Inc shares were sold for 60.5% higher than average price of previous purchases. This sale made a profit of USD 12,832 The average price that the ETF previously sold STOK share for is USD 17.368 so the ETF has sold 1068 shares on 2025-12-23 at a higher price than the previous selling average. |
| HROW - Harrow Health Inc | SELL | -696 @ USD 49.15 | USD -34,208 | The ETF sold 696 shares of HROW on 2025-12-23. The shares were previously bought for an average price of USD 37.2233. The Harrow Health Inc shares were sold for 32.0% higher than average price of previous purchases. This sale made a profit of USD 8,301 The average price that the ETF previously sold HROW share for is USD 36.2963 so the ETF has sold 696 shares on 2025-12-23 at a higher price than the previous selling average. |
| MNKD - MannKind Corp | SELL | -5,772 @ USD 5.93 | USD -34,228 | The ETF sold 5772 shares of MNKD on 2025-12-23. The shares were previously bought for an average price of USD 4.97976. The MannKind Corp shares were sold for 19.1% higher than average price of previous purchases. This sale made a profit of USD 5,485 The average price that the ETF previously sold MNKD share for is USD 5.70749 so the ETF has sold 5772 shares on 2025-12-23 at a higher price than the previous selling average. |
| SNDX - Syndax Pharmaceuticals Inc | SELL | -1,632 @ USD 21.7 | USD -35,414 | The ETF sold 1632 shares of SNDX on 2025-12-23. The shares were previously bought for an average price of USD 14.1601. The Syndax Pharmaceuticals Inc shares were sold for 53.2% higher than average price of previous purchases. This sale made a profit of USD 12,305 The average price that the ETF previously sold SNDX share for is USD 15.2486 so the ETF has sold 1632 shares on 2025-12-23 at a higher price than the previous selling average. |
| VCEL - Vericel Corp Ord | SELL | -948 @ USD 37.38 | USD -35,436 | The ETF sold 948 shares of VCEL on 2025-12-23. The shares were previously bought for an average price of USD 39.8793. The Vericel Corp Ord shares were sold for -6.3% lower than average price of previous purchases. This resulted in an overall loss of USD 2,369 The average price that the ETF previously sold VCEL share for is USD 44.5062 which is higher than the selling price of USD 37.38 on 2025-12-23. |
| KNSA - Kiniksa Pharmaceuticals Ltd | SELL | -840 @ USD 42.52 | USD -35,717 | The ETF sold 840 shares of KNSA on 2025-12-23. The shares were previously bought for an average price of USD 32.9161. The Kiniksa Pharmaceuticals Ltd shares were sold for 29.2% higher than average price of previous purchases. This sale made a profit of USD 8,067 The average price that the ETF previously sold KNSA share for is USD 26.8904 so the ETF has sold 840 shares on 2025-12-23 at a higher price than the previous selling average. |
| LEGN - Legend Biotech Corp | SELL | -1,572 @ USD 22.85 | USD -35,920 | The ETF sold 1572 shares of LEGN on 2025-12-23. The shares were previously bought for an average price of USD 32.55. The Legend Biotech Corp shares were sold for -29.8% lower than average price of previous purchases. This resulted in an overall loss of USD 15,248 The average price that the ETF previously sold LEGN share for is USD 31.4541 which is higher than the selling price of USD 22.85 on 2025-12-23. |
| TXG - 10X Genomics Inc | SELL | -2,184 @ USD 16.5 | USD -36,036 | The ETF sold 2184 shares of TXG on 2025-12-23. The shares were previously bought for an average price of USD 13.6014. The 10X Genomics Inc shares were sold for 21.3% higher than average price of previous purchases. This sale made a profit of USD 6,331 The average price that the ETF previously sold TXG share for is USD 12.4575 so the ETF has sold 2184 shares on 2025-12-23 at a higher price than the previous selling average. |
| TXG - Terex Corporation | SELL | -2,184 @ USD 16.5 | USD -36,036 | The ETF sold 2184 shares of TXG on 2025-12-23. The shares were previously bought for an average price of USD 13.6014. The Terex Corporation shares were sold for 21.3% higher than average price of previous purchases. This sale made a profit of USD 6,331 The average price that the ETF previously sold TXG share for is USD 12.4575 so the ETF has sold 2184 shares on 2025-12-23 at a higher price than the previous selling average. |
| NRIX - Nurix Therapeutics Inc | SELL | -1,896 @ USD 19.29 | USD -36,574 | The ETF sold 1896 shares of NRIX on 2025-12-23. The shares were previously bought for an average price of USD 14.6691. The Nurix Therapeutics Inc shares were sold for 31.5% higher than average price of previous purchases. This sale made a profit of USD 8,761 The average price that the ETF previously sold NRIX share for is USD 14.7841 so the ETF has sold 1896 shares on 2025-12-23 at a higher price than the previous selling average. |
| GMAB - Genmab AS | SELL | -1,092 @ USD 33.65 | USD -36,746 | The ETF sold 1092 shares of GMAB on 2025-12-23. The shares were previously bought for an average price of USD 28.2532. The Genmab AS shares were sold for 19.1% higher than average price of previous purchases. This sale made a profit of USD 5,893 The average price that the ETF previously sold GMAB share for is USD 21.7999 so the ETF has sold 1092 shares on 2025-12-23 at a higher price than the previous selling average. |
| ZYME - Zymeworks Inc. Common Stock | SELL | -1,404 @ USD 26.79 | USD -37,613 | The ETF sold 1404 shares of ZYME on 2025-12-23. The shares were previously bought for an average price of USD 17.4588. The Zymeworks Inc. Common Stock shares were sold for 53.4% higher than average price of previous purchases. This sale made a profit of USD 13,101 The average price that the ETF previously sold ZYME share for is USD 17.6718 so the ETF has sold 1404 shares on 2025-12-23 at a higher price than the previous selling average. |
| TWST - Twist Bioscience Corp | SELL | -1,140 @ USD 33.84 | USD -38,578 | The ETF sold 1140 shares of TWST on 2025-12-23. The shares were previously bought for an average price of USD 34.5907. The Twist Bioscience Corp shares were sold for -2.2% lower than average price of previous purchases. This resulted in an overall loss of USD 856 The average price that the ETF previously sold TWST share for is USD 38.3993 which is higher than the selling price of USD 33.84 on 2025-12-23. |
| IBRX - Immunitybio Inc | SELL | -18,468 @ USD 2.1 | USD -38,783 | The ETF sold 18468 shares of IBRX on 2025-12-23. The shares were previously bought for an average price of USD 2.63096. The Immunitybio Inc shares were sold for -20.2% lower than average price of previous purchases. This resulted in an overall loss of USD 9,806 The average price that the ETF previously sold IBRX share for is USD 2.85939 which is higher than the selling price of USD 2.1 on 2025-12-23. |
| AUPH - Aurinia Pharmaceuticals Inc | SELL | -2,472 @ USD 16.21 | USD -40,071 | The ETF sold 2472 shares of AUPH on 2025-12-23. The shares were previously bought for an average price of USD 11.4185. The Aurinia Pharmaceuticals Inc shares were sold for 42.0% higher than average price of previous purchases. This sale made a profit of USD 11,845 The average price that the ETF previously sold AUPH share for is USD 10.8361 so the ETF has sold 2472 shares on 2025-12-23 at a higher price than the previous selling average. |
| OLMA - Olema Pharmaceuticals Inc | SELL | -1,476 @ USD 27.67 | USD -40,841 | The ETF sold 1476 shares of OLMA on 2025-12-23. The shares were previously bought for an average price of USD 12.7927. The Olema Pharmaceuticals Inc shares were sold for 116.3% higher than average price of previous purchases. This sale made a profit of USD 21,959 The average price that the ETF previously sold OLMA share for is USD 8.20015 so the ETF has sold 1476 shares on 2025-12-23 at a higher price than the previous selling average. |
| HRMY - Harmony Biosciences Holdings | SELL | -1,080 @ USD 38.44 | USD -41,515 | The ETF sold 1080 shares of HRMY on 2025-12-23. The shares were previously bought for an average price of USD 33.4092. The Harmony Biosciences Holdings shares were sold for 15.1% higher than average price of previous purchases. This sale made a profit of USD 5,433 The average price that the ETF previously sold HRMY share for is USD 34.2201 so the ETF has sold 1080 shares on 2025-12-23 at a higher price than the previous selling average. |
| RXRX - Recursion Pharmaceuticals Inc | SELL | -9,648 @ USD 4.36 | USD -42,065 | The ETF sold 9648 shares of RXRX on 2025-12-23. The shares were previously bought for an average price of USD 5.29733. The Recursion Pharmaceuticals Inc shares were sold for -17.7% lower than average price of previous purchases. This resulted in an overall loss of USD 9,043 The average price that the ETF previously sold RXRX share for is USD 5.44505 which is higher than the selling price of USD 4.36 on 2025-12-23. |
| EWTX - Edgewise Therapeutics Inc | SELL | -1,980 @ USD 21.745 | USD -43,055 | The ETF sold 1980 shares of EWTX on 2025-12-23. The shares were previously bought for an average price of USD 18.0442. The Edgewise Therapeutics Inc shares were sold for 20.5% higher than average price of previous purchases. This sale made a profit of USD 7,328 The average price that the ETF previously sold EWTX share for is USD 23.5691 which is higher than the selling price of USD 21.745 on 2025-12-23. |
| SRPT - Sarepta Therapeutics Inc | SELL | -1,992 @ USD 22 | USD -43,824 | The ETF sold 1992 shares of SRPT on 2025-12-23. The shares were previously bought for an average price of USD 30.2726. The Sarepta Therapeutics Inc shares were sold for -27.3% lower than average price of previous purchases. This resulted in an overall loss of USD 16,479 The average price that the ETF previously sold SRPT share for is USD 81.1514 which is higher than the selling price of USD 22 on 2025-12-23. |
| CNTA - Centessa Pharmaceuticals PLC ADR | SELL | -1,800 @ USD 25.26 | USD -45,468 | The ETF sold 1800 shares of CNTA on 2025-12-23. The shares were previously bought for an average price of USD 19.607. The Centessa Pharmaceuticals PLC ADR shares were sold for 28.8% higher than average price of previous purchases. This sale made a profit of USD 10,175 The average price that the ETF previously sold CNTA share for is USD 19.3128 so the ETF has sold 1800 shares on 2025-12-23 at a higher price than the previous selling average. |
| DNLI - Denali Therapeutics Inc | SELL | -2,748 @ USD 16.81 | USD -46,194 | The ETF sold 2748 shares of DNLI on 2025-12-23. The shares were previously bought for an average price of USD 16.2138. The Denali Therapeutics Inc shares were sold for 3.7% higher than average price of previous purchases. This sale made a profit of USD 1,638 The average price that the ETF previously sold DNLI share for is USD 17.5842 which is higher than the selling price of USD 16.81 on 2025-12-23. |
| ADPT - Adaptive Biotechnologies Corp | SELL | -2,856 @ USD 16.75 | USD -47,838 | The ETF sold 2856 shares of ADPT on 2025-12-23. The shares were previously bought for an average price of USD 13.5056. The Adaptive Biotechnologies Corp shares were sold for 24.0% higher than average price of previous purchases. This sale made a profit of USD 9,266 The average price that the ETF previously sold ADPT share for is USD 9.90638 so the ETF has sold 2856 shares on 2025-12-23 at a higher price than the previous selling average. |
| SYRE - Spyre Therapeutics Inc. | SELL | -1,452 @ USD 33.23 | USD -48,250 | The ETF sold 1452 shares of SYRE on 2025-12-23. The shares were previously bought for an average price of USD 24.6779. The Spyre Therapeutics Inc. shares were sold for 34.7% higher than average price of previous purchases. This sale made a profit of USD 12,418 The average price that the ETF previously sold SYRE share for is USD 18.3804 so the ETF has sold 1452 shares on 2025-12-23 at a higher price than the previous selling average. |
| OCUL - Ocular Therapeutix Inc | SELL | -3,996 @ USD 12.74 | USD -50,909 | The ETF sold 3996 shares of OCUL on 2025-12-23. The shares were previously bought for an average price of USD 11.005. The Ocular Therapeutix Inc shares were sold for 15.8% higher than average price of previous purchases. This sale made a profit of USD 6,933 The average price that the ETF previously sold OCUL share for is USD 8.88114 so the ETF has sold 3996 shares on 2025-12-23 at a higher price than the previous selling average. |
| BEAM - Beam Therapeutics Inc | SELL | -1,896 @ USD 27.77 | USD -52,652 | The ETF sold 1896 shares of BEAM on 2025-12-23. The shares were previously bought for an average price of USD 21.9747. The Beam Therapeutics Inc shares were sold for 26.4% higher than average price of previous purchases. This sale made a profit of USD 10,988 The average price that the ETF previously sold BEAM share for is USD 23.9361 so the ETF has sold 1896 shares on 2025-12-23 at a higher price than the previous selling average. |
| DYN - Dyne Therapeutics Inc | SELL | -2,676 @ USD 20.41 | USD -54,617 | The ETF sold 2676 shares of DYN on 2025-12-23. The shares were previously bought for an average price of USD 14.9005. The Dyne Therapeutics Inc shares were sold for 37.0% higher than average price of previous purchases. This sale made a profit of USD 14,743 The average price that the ETF previously sold DYN share for is USD 18.1753 so the ETF has sold 2676 shares on 2025-12-23 at a higher price than the previous selling average. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | SELL | -2,676 @ USD 20.41 | USD -54,617 | The ETF sold 2676 shares of DYN on 2025-12-23. The shares were previously bought for an average price of USD 14.9005. The DYNAGREEN EN.PR.GR.H YC 1 shares were sold for 37.0% higher than average price of previous purchases. This sale made a profit of USD 14,743 The average price that the ETF previously sold DYN share for is USD 18.1753 so the ETF has sold 2676 shares on 2025-12-23 at a higher price than the previous selling average. |
| WVE - Wave Life Sciences Ltd | SELL | -3,132 @ USD 17.48 | USD -54,747 | The ETF sold 3132 shares of WVE on 2025-12-23. The shares were previously bought for an average price of USD 8.32984. The Wave Life Sciences Ltd shares were sold for 109.8% higher than average price of previous purchases. This sale made a profit of USD 28,658 The average price that the ETF previously sold WVE share for is USD 10.6365 so the ETF has sold 3132 shares on 2025-12-23 at a higher price than the previous selling average. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | SELL | -1,476 @ USD 37.35 | USD -55,129 | The ETF sold 1476 shares of MLYS on 2025-12-23. The shares were previously bought for an average price of USD 26.3812. The Mineralys Therapeutics, Inc. Common Stock shares were sold for 41.6% higher than average price of previous purchases. This sale made a profit of USD 16,190 The average price that the ETF previously sold MLYS share for is USD 17.0308 so the ETF has sold 1476 shares on 2025-12-23 at a higher price than the previous selling average. |
| SUPN - Supernus Pharmaceuticals Inc | SELL | -1,068 @ USD 51.71 | USD -55,226 | The ETF sold 1068 shares of SUPN on 2025-12-23. The shares were previously bought for an average price of USD 39.6336. The Supernus Pharmaceuticals Inc shares were sold for 30.5% higher than average price of previous purchases. This sale made a profit of USD 12,898 The average price that the ETF previously sold SUPN share for is USD 38.6891 so the ETF has sold 1068 shares on 2025-12-23 at a higher price than the previous selling average. |
| IRON - Ironveld Plc | SELL | -696 @ USD 79.82 | USD -55,555 | The ETF sold 696 shares of IRON on 2025-12-23. The shares were previously bought for an average price of USD 66.3852. The Ironveld Plc shares were sold for 20.2% higher than average price of previous purchases. This sale made a profit of USD 9,351 The average price that the ETF previously sold IRON share for is USD 58.6355 so the ETF has sold 696 shares on 2025-12-23 at a higher price than the previous selling average. |
| IDYA - Ideaya Biosciences Inc | SELL | -1,632 @ USD 35.41 | USD -57,789 | The ETF sold 1632 shares of IDYA on 2025-12-23. The shares were previously bought for an average price of USD 26.2915. The Ideaya Biosciences Inc shares were sold for 34.7% higher than average price of previous purchases. This sale made a profit of USD 14,881 The average price that the ETF previously sold IDYA share for is USD 25.6207 so the ETF has sold 1632 shares on 2025-12-23 at a higher price than the previous selling average. |
| APLS - Apellis Pharmaceuticals Inc | SELL | -2,364 @ USD 24.82 | USD -58,674 | The ETF sold 2364 shares of APLS on 2025-12-23. The shares were previously bought for an average price of USD 21.1742. The Apellis Pharmaceuticals Inc shares were sold for 17.2% higher than average price of previous purchases. This sale made a profit of USD 8,619 The average price that the ETF previously sold APLS share for is USD 25.1432 which is higher than the selling price of USD 24.82 on 2025-12-23. |
| TVTX - Travere Therapeutics Inc | SELL | -1,668 @ USD 35.36 | USD -58,980 | The ETF sold 1668 shares of TVTX on 2025-12-23. The shares were previously bought for an average price of USD 24.3859. The Travere Therapeutics Inc shares were sold for 45.0% higher than average price of previous purchases. This sale made a profit of USD 18,305 The average price that the ETF previously sold TVTX share for is USD 24.0497 so the ETF has sold 1668 shares on 2025-12-23 at a higher price than the previous selling average. |
| CGON - CG Oncology, Inc. Common stock | SELL | -1,500 @ USD 40.05 | USD -60,075 | The ETF sold 1500 shares of CGON on 2025-12-23. The shares were previously bought for an average price of USD 33.194. The CG Oncology, Inc. Common stock shares were sold for 20.7% higher than average price of previous purchases. This sale made a profit of USD 10,284 The average price that the ETF previously sold CGON share for is USD 29.1786 so the ETF has sold 1500 shares on 2025-12-23 at a higher price than the previous selling average. |
| RARE - Ultragenyx | SELL | -1,800 @ USD 34.13 | USD -61,434 | The ETF sold 1800 shares of RARE on 2025-12-23. The shares were previously bought for an average price of USD 35.9847. The Ultragenyx shares were sold for -5.2% lower than average price of previous purchases. This resulted in an overall loss of USD 3,338 The average price that the ETF previously sold RARE share for is USD 37.1884 which is higher than the selling price of USD 34.13 on 2025-12-23. |
| RARE - WISETFWTMRARETFP | SELL | -1,800 @ USD 34.13 | USD -61,434 | The ETF sold 1800 shares of RARE on 2025-12-23. The shares were previously bought for an average price of USD 35.9847. The WISETFWTMRARETFP shares were sold for -5.2% lower than average price of previous purchases. This resulted in an overall loss of USD 3,338 The average price that the ETF previously sold RARE share for is USD 37.1884 which is higher than the selling price of USD 34.13 on 2025-12-23. |
| VCYT - Veracyte Inc | SELL | -1,476 @ USD 42.92 | USD -63,350 | The ETF sold 1476 shares of VCYT on 2025-12-23. The shares were previously bought for an average price of USD 35.1548. The Veracyte Inc shares were sold for 22.1% higher than average price of previous purchases. This sale made a profit of USD 11,461 The average price that the ETF previously sold VCYT share for is USD 36.6854 so the ETF has sold 1476 shares on 2025-12-23 at a higher price than the previous selling average. |
| VERA - Vera Therapeutics Inc | SELL | -1,188 @ USD 53.91 | USD -64,045 | The ETF sold 1188 shares of VERA on 2025-12-23. The shares were previously bought for an average price of USD 30.451. The Vera Therapeutics Inc shares were sold for 77.0% higher than average price of previous purchases. This sale made a profit of USD 27,869 The average price that the ETF previously sold VERA share for is USD 37.3036 so the ETF has sold 1188 shares on 2025-12-23 at a higher price than the previous selling average. |
| XENE - Xenon Pharmaceuticals Inc | SELL | -1,440 @ USD 44.54 | USD -64,138 | The ETF sold 1440 shares of XENE on 2025-12-23. The shares were previously bought for an average price of USD 37.74. The Xenon Pharmaceuticals Inc shares were sold for 18.0% higher than average price of previous purchases. This sale made a profit of USD 9,792 The average price that the ETF previously sold XENE share for is USD 38.2642 so the ETF has sold 1440 shares on 2025-12-23 at a higher price than the previous selling average. |
| TARS - Tarsus Pharmaceuticals Inc | SELL | -792 @ USD 82.13 | USD -65,047 | The ETF sold 792 shares of TARS on 2025-12-23. The shares were previously bought for an average price of USD 57.0634. The Tarsus Pharmaceuticals Inc shares were sold for 43.9% higher than average price of previous purchases. This sale made a profit of USD 19,853 The average price that the ETF previously sold TARS share for is USD 58.5171 so the ETF has sold 792 shares on 2025-12-23 at a higher price than the previous selling average. |
| GRAL - GRAIL, LLC | SELL | -720 @ USD 91.39 | USD -65,801 | The ETF sold 720 shares of GRAL on 2025-12-23. The shares were previously bought for an average price of USD 64.6396. The GRAIL, LLC shares were sold for 41.4% higher than average price of previous purchases. This sale made a profit of USD 19,260 The average price that the ETF previously sold GRAL share for is USD 36.0525 so the ETF has sold 720 shares on 2025-12-23 at a higher price than the previous selling average. |
| ARQT - Arcutis Biotherapeutics Inc | SELL | -2,292 @ USD 29.31 | USD -67,179 | The ETF sold 2292 shares of ARQT on 2025-12-23. The shares were previously bought for an average price of USD 20.3067. The Arcutis Biotherapeutics Inc shares were sold for 44.3% higher than average price of previous purchases. This sale made a profit of USD 20,636 The average price that the ETF previously sold ARQT share for is USD 17.4264 so the ETF has sold 2292 shares on 2025-12-23 at a higher price than the previous selling average. |
| TERN - Tern Plc | SELL | -1,680 @ USD 41.53 | USD -69,770 | The ETF sold 1680 shares of TERN on 2025-12-23. The shares were previously bought for an average price of USD 11.7882. The Tern Plc shares were sold for 252.3% higher than average price of previous purchases. This sale made a profit of USD 49,966 The average price that the ETF previously sold TERN share for is USD 14.9115 so the ETF has sold 1680 shares on 2025-12-23 at a higher price than the previous selling average. |
| ACLX - Arcellx Inc | SELL | -1,080 @ USD 65.51 | USD -70,751 | The ETF sold 1080 shares of ACLX on 2025-12-23. The shares were previously bought for an average price of USD 72.2348. The Arcellx Inc shares were sold for -9.3% lower than average price of previous purchases. This resulted in an overall loss of USD 7,263 The average price that the ETF previously sold ACLX share for is USD 73.1096 which is higher than the selling price of USD 65.51 on 2025-12-23. |
| LGND - Ligand Pharmaceuticals Incorporated | SELL | -372 @ USD 197.39 | USD -73,429 | The ETF sold 372 shares of LGND on 2025-12-23. The shares were previously bought for an average price of USD 149.754. The Ligand Pharmaceuticals Incorporated shares were sold for 31.8% higher than average price of previous purchases. This sale made a profit of USD 17,721 The average price that the ETF previously sold LGND share for is USD 138.198 so the ETF has sold 372 shares on 2025-12-23 at a higher price than the previous selling average. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | SELL | -5,880 @ USD 12.84 | USD -75,499 | The ETF sold 5880 shares of AMRX on 2025-12-23. The shares were previously bought for an average price of USD 9.67809. The Amneal Pharmaceuticals, Inc. Class A Common Stock shares were sold for 32.7% higher than average price of previous purchases. This sale made a profit of USD 18,592 The average price that the ETF previously sold AMRX share for is USD 10.1141 so the ETF has sold 5880 shares on 2025-12-23 at a higher price than the previous selling average. |
| MIRM - Mirum Pharmaceuticals Inc | SELL | -960 @ USD 80.05 | USD -76,848 | The ETF sold 960 shares of MIRM on 2025-12-23. The shares were previously bought for an average price of USD 59.567. The Mirum Pharmaceuticals Inc shares were sold for 34.4% higher than average price of previous purchases. This sale made a profit of USD 19,664 The average price that the ETF previously sold MIRM share for is USD 51.7673 so the ETF has sold 960 shares on 2025-12-23 at a higher price than the previous selling average. |
| APGE - Apogee Therapeutics, Inc. Common Stock | SELL | -1,020 @ USD 77.3 | USD -78,846 | The ETF sold 1020 shares of APGE on 2025-12-23. The shares were previously bought for an average price of USD 56.7109. The Apogee Therapeutics, Inc. Common Stock shares were sold for 36.3% higher than average price of previous purchases. This sale made a profit of USD 21,001 The average price that the ETF previously sold APGE share for is USD 43.9529 so the ETF has sold 1020 shares on 2025-12-23 at a higher price than the previous selling average. |
| FOLD - Amicus Therapeutics Inc | SELL | -5,772 @ USD 14.21 | USD -82,020 | The ETF sold 5772 shares of FOLD on 2025-12-23. The shares were previously bought for an average price of USD 8.13244. The Amicus Therapeutics Inc shares were sold for 74.7% higher than average price of previous purchases. This sale made a profit of USD 35,080 The average price that the ETF previously sold FOLD share for is USD 10.0547 so the ETF has sold 5772 shares on 2025-12-23 at a higher price than the previous selling average. |
| ADMA - ADMA Biologics Inc | SELL | -4,452 @ USD 19.49 | USD -86,769 | The ETF sold 4452 shares of ADMA on 2025-12-23. The shares were previously bought for an average price of USD 17.8131. The ADMA Biologics Inc shares were sold for 9.4% higher than average price of previous purchases. This sale made a profit of USD 7,466 The average price that the ETF previously sold ADMA share for is USD 18.4706 so the ETF has sold 4452 shares on 2025-12-23 at a higher price than the previous selling average. |
| CRNX - Crinetics Pharmaceuticals Inc | SELL | -1,776 @ USD 48.87 | USD -86,793 | The ETF sold 1776 shares of CRNX on 2025-12-23. The shares were previously bought for an average price of USD 38.1494. The Crinetics Pharmaceuticals Inc shares were sold for 28.1% higher than average price of previous purchases. This sale made a profit of USD 19,040 The average price that the ETF previously sold CRNX share for is USD 41.1287 so the ETF has sold 1776 shares on 2025-12-23 at a higher price than the previous selling average. |
| IMVT - Immunovant Inc | SELL | -3,276 @ USD 26.76 | USD -87,666 | The ETF sold 3276 shares of IMVT on 2025-12-23. The shares were previously bought for an average price of USD 19.2313. The Immunovant Inc shares were sold for 39.1% higher than average price of previous purchases. This sale made a profit of USD 24,664 The average price that the ETF previously sold IMVT share for is USD 22.489 so the ETF has sold 3276 shares on 2025-12-23 at a higher price than the previous selling average. |
| ACAD - ACADIA Pharmaceuticals Inc | SELL | -3,156 @ USD 27.83 | USD -87,831 | The ETF sold 3156 shares of ACAD on 2025-12-23. The shares were previously bought for an average price of USD 22.1074. The ACADIA Pharmaceuticals Inc shares were sold for 25.9% higher than average price of previous purchases. This sale made a profit of USD 18,061 The average price that the ETF previously sold ACAD share for is USD 20.0245 so the ETF has sold 3156 shares on 2025-12-23 at a higher price than the previous selling average. |
| ALKS - Alkermes Plc | SELL | -3,084 @ USD 28.49 | USD -87,863 | The ETF sold 3084 shares of ALKS on 2025-12-23. The shares were previously bought for an average price of USD 30.0612. The Alkermes Plc shares were sold for -5.2% lower than average price of previous purchases. This resulted in an overall loss of USD 4,846 The average price that the ETF previously sold ALKS share for is USD 29.3588 which is higher than the selling price of USD 28.49 on 2025-12-23. |
| SRRK - Scholar Rock Holding Corp | SELL | -1,920 @ USD 45.89 | USD -88,109 | The ETF sold 1920 shares of SRRK on 2025-12-23. The shares were previously bought for an average price of USD 36.9091. The Scholar Rock Holding Corp shares were sold for 24.3% higher than average price of previous purchases. This sale made a profit of USD 17,243 The average price that the ETF previously sold SRRK share for is USD 32.5935 so the ETF has sold 1920 shares on 2025-12-23 at a higher price than the previous selling average. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | SELL | -1,248 @ USD 71.29 | USD -88,970 | The ETF sold 1248 shares of GPCR on 2025-12-23. The shares were previously bought for an average price of USD 31.0398. The Structure Therapeutics Inc. American Depositary Shares shares were sold for 129.7% higher than average price of previous purchases. This sale made a profit of USD 50,232 The average price that the ETF previously sold GPCR share for is USD 26.2219 so the ETF has sold 1248 shares on 2025-12-23 at a higher price than the previous selling average. |
| CRSP - Crispr Therapeutics AG | SELL | -1,776 @ USD 56.46 | USD -100,273 | The ETF sold 1776 shares of CRSP on 2025-12-23. The shares were previously bought for an average price of USD 53.2024. The Crispr Therapeutics AG shares were sold for 6.1% higher than average price of previous purchases. This sale made a profit of USD 5,785 The average price that the ETF previously sold CRSP share for is USD 45.1847 so the ETF has sold 1776 shares on 2025-12-23 at a higher price than the previous selling average. |
| PTGX - Protagonist Therapeutics Inc | SELL | -1,164 @ USD 88.73 | USD -103,282 | The ETF sold 1164 shares of PTGX on 2025-12-23. The shares were previously bought for an average price of USD 65.1832. The Protagonist Therapeutics Inc shares were sold for 36.1% higher than average price of previous purchases. This sale made a profit of USD 27,408 The average price that the ETF previously sold PTGX share for is USD 58.2615 so the ETF has sold 1164 shares on 2025-12-23 at a higher price than the previous selling average. |
| KYMR - Kymera Therapeutics Inc | SELL | -1,344 @ USD 83.53 | USD -112,264 | The ETF sold 1344 shares of KYMR on 2025-12-23. The shares were previously bought for an average price of USD 52.7782. The Kymera Therapeutics Inc shares were sold for 58.3% higher than average price of previous purchases. This sale made a profit of USD 41,330 The average price that the ETF previously sold KYMR share for is USD 51.1192 so the ETF has sold 1344 shares on 2025-12-23 at a higher price than the previous selling average. |
| COGT - Cogent Biosciences Inc | SELL | -2,868 @ USD 40.17 | USD -115,208 | The ETF sold 2868 shares of COGT on 2025-12-23. The shares were previously bought for an average price of USD 20.0773. The Cogent Biosciences Inc shares were sold for 100.1% higher than average price of previous purchases. This sale made a profit of USD 57,626 The average price that the ETF previously sold COGT share for is USD 11.2616 so the ETF has sold 2868 shares on 2025-12-23 at a higher price than the previous selling average. |
| PTCT - PTC Therapeutics Inc | SELL | -1,500 @ USD 77.7 | USD -116,550 | The ETF sold 1500 shares of PTCT on 2025-12-23. The shares were previously bought for an average price of USD 61.5052. The PTC Therapeutics Inc shares were sold for 26.3% higher than average price of previous purchases. This sale made a profit of USD 24,292 The average price that the ETF previously sold PTCT share for is USD 55.7339 so the ETF has sold 1500 shares on 2025-12-23 at a higher price than the previous selling average. |
| PCVX - Vaxcyte Inc | SELL | -2,448 @ USD 47.81 | USD -117,039 | The ETF sold 2448 shares of PCVX on 2025-12-23. The shares were previously bought for an average price of USD 45.2658. The Vaxcyte Inc shares were sold for 5.6% higher than average price of previous purchases. This sale made a profit of USD 6,228 The average price that the ETF previously sold PCVX share for is USD 53.9499 which is higher than the selling price of USD 47.81 on 2025-12-23. |
| PRAX - Praxis Precision Medicines Inc | SELL | -468 @ USD 275.73 | USD -129,042 | The ETF sold 468 shares of PRAX on 2025-12-23. The shares were previously bought for an average price of USD 125.803. The Praxis Precision Medicines Inc shares were sold for 119.2% higher than average price of previous purchases. This sale made a profit of USD 70,166 The average price that the ETF previously sold PRAX share for is USD 80.1651 so the ETF has sold 468 shares on 2025-12-23 at a higher price than the previous selling average. |
| KRYS - Krystal Biotech Inc | SELL | -540 @ USD 253.36 | USD -136,814 | The ETF sold 540 shares of KRYS on 2025-12-23. The shares were previously bought for an average price of USD 178.182. The Krystal Biotech Inc shares were sold for 42.2% higher than average price of previous purchases. This sale made a profit of USD 40,596 The average price that the ETF previously sold KRYS share for is USD 187.409 so the ETF has sold 540 shares on 2025-12-23 at a higher price than the previous selling average. |
| RYTM - Rhythm Pharmaceuticals Inc | SELL | -1,248 @ USD 112.35 | USD -140,213 | The ETF sold 1248 shares of RYTM on 2025-12-23. The shares were previously bought for an average price of USD 83.9526. The Rhythm Pharmaceuticals Inc shares were sold for 33.8% higher than average price of previous purchases. This sale made a profit of USD 35,440 The average price that the ETF previously sold RYTM share for is USD 76.5515 so the ETF has sold 1248 shares on 2025-12-23 at a higher price than the previous selling average. |
| NUVL - Nuvalent Inc | SELL | -1,344 @ USD 104.83 | USD -140,892 | The ETF sold 1344 shares of NUVL on 2025-12-23. The shares were previously bought for an average price of USD 88.9595. The Nuvalent Inc shares were sold for 17.8% higher than average price of previous purchases. This sale made a profit of USD 21,330 The average price that the ETF previously sold NUVL share for is USD 81.0674 so the ETF has sold 1344 shares on 2025-12-23 at a higher price than the previous selling average. |
| CYTK - Cytokinetics Inc | SELL | -2,280 @ USD 63.29 | USD -144,301 | The ETF sold 2280 shares of CYTK on 2025-12-23. The shares were previously bought for an average price of USD 49.2666. The Cytokinetics Inc shares were sold for 28.5% higher than average price of previous purchases. This sale made a profit of USD 31,973 The average price that the ETF previously sold CYTK share for is USD 49.7542 so the ETF has sold 2280 shares on 2025-12-23 at a higher price than the previous selling average. |
| AXSM - Axsome Therapeutics Inc | SELL | -936 @ USD 154.19 | USD -144,322 | The ETF sold 936 shares of AXSM on 2025-12-23. The shares were previously bought for an average price of USD 124.03. The Axsome Therapeutics Inc shares were sold for 24.3% higher than average price of previous purchases. This sale made a profit of USD 28,230 The average price that the ETF previously sold AXSM share for is USD 114.714 so the ETF has sold 936 shares on 2025-12-23 at a higher price than the previous selling average. |
| HALO - Halozyme Therapeutics Inc | SELL | -2,196 @ USD 68.36 | USD -150,119 | The ETF sold 2196 shares of HALO on 2025-12-23. The shares were previously bought for an average price of USD 61.6901. The Halozyme Therapeutics Inc shares were sold for 10.8% higher than average price of previous purchases. This sale made a profit of USD 14,647 The average price that the ETF previously sold HALO share for is USD 57.3162 so the ETF has sold 2196 shares on 2025-12-23 at a higher price than the previous selling average. |
| ARWR - Arrowhead Pharmaceuticals Inc | SELL | -2,532 @ USD 69.83 | USD -176,810 | The ETF sold 2532 shares of ARWR on 2025-12-23. The shares were previously bought for an average price of USD 30.5514. The Arrowhead Pharmaceuticals Inc shares were sold for 128.6% higher than average price of previous purchases. This sale made a profit of USD 99,453 The average price that the ETF previously sold ARWR share for is USD 34.076 so the ETF has sold 2532 shares on 2025-12-23 at a higher price than the previous selling average. |
| BNTX - BioNTech SE | SELL | -1,884 @ USD 94.14 | USD -177,360 | The ETF sold 1884 shares of BNTX on 2025-12-23. The shares were previously bought for an average price of USD 102.872. The BioNTech SE shares were sold for -8.5% lower than average price of previous purchases. This resulted in an overall loss of USD 16,451 The average price that the ETF previously sold BNTX share for is USD 101.29 which is higher than the selling price of USD 94.14 on 2025-12-23. |
| JAZZ - Jazz Pharmaceuticals PLC | SELL | -1,140 @ USD 169.47 | USD -193,196 | The ETF sold 1140 shares of JAZZ on 2025-12-23. The shares were previously bought for an average price of USD 135.895. The Jazz Pharmaceuticals PLC shares were sold for 24.7% higher than average price of previous purchases. This sale made a profit of USD 38,275 The average price that the ETF previously sold JAZZ share for is USD 134.629 so the ETF has sold 1140 shares on 2025-12-23 at a higher price than the previous selling average. |
| RNA - Avidity Biosciences Inc | SELL | -2,808 @ USD 72.14 | USD -202,569 | The ETF sold 2808 shares of RNA on 2025-12-23. The shares were previously bought for an average price of USD 50.9908. The Avidity Biosciences Inc shares were sold for 41.5% higher than average price of previous purchases. This sale made a profit of USD 59,387 The average price that the ETF previously sold RNA share for is USD 36.208 so the ETF has sold 2808 shares on 2025-12-23 at a higher price than the previous selling average. |
| BMRN - Biomarin Pharmaceutical Inc | SELL | -3,588 @ USD 61.14 | USD -219,370 | The ETF sold 3588 shares of BMRN on 2025-12-23. The shares were previously bought for an average price of USD 57.025. The Biomarin Pharmaceutical Inc shares were sold for 7.2% higher than average price of previous purchases. This sale made a profit of USD 14,765 The average price that the ETF previously sold BMRN share for is USD 62.1159 which is higher than the selling price of USD 61.14 on 2025-12-23. |
| EXEL - Exelixis Inc | SELL | -5,004 @ USD 46.61 | USD -233,236 | The ETF sold 5004 shares of EXEL on 2025-12-23. The shares were previously bought for an average price of USD 41.7182. The Exelixis Inc shares were sold for 11.7% higher than average price of previous purchases. This sale made a profit of USD 24,479 The average price that the ETF previously sold EXEL share for is USD 38.1762 so the ETF has sold 5004 shares on 2025-12-23 at a higher price than the previous selling average. |
| MRNA - Moderna Inc | SELL | -7,296 @ USD 32.29 | USD -235,588 | The ETF sold 7296 shares of MRNA on 2025-12-23. The shares were previously bought for an average price of USD 28.0088. The Moderna Inc shares were sold for 15.3% higher than average price of previous purchases. This sale made a profit of USD 31,236 The average price that the ETF previously sold MRNA share for is USD 34.2009 which is higher than the selling price of USD 32.29 on 2025-12-23. |
| ASND - Ascendis Pharma AS | SELL | -1,140 @ USD 209.23 | USD -238,522 | The ETF sold 1140 shares of ASND on 2025-12-23. The shares were previously bought for an average price of USD 186.741. The Ascendis Pharma AS shares were sold for 12.0% higher than average price of previous purchases. This sale made a profit of USD 25,637 The average price that the ETF previously sold ASND share for is USD 163.646 so the ETF has sold 1140 shares on 2025-12-23 at a higher price than the previous selling average. |
| SNY - Sanofi ADR | SELL | -4,944 @ USD 48.32 | USD -238,894 | The ETF sold 4944 shares of SNY on 2025-12-23. The shares were previously bought for an average price of USD 49.8849. The Sanofi ADR shares were sold for -3.1% lower than average price of previous purchases. This resulted in an overall loss of USD 7,737 The average price that the ETF previously sold SNY share for is USD 50.098 which is higher than the selling price of USD 48.32 on 2025-12-23. |
| IONS - Ionis Pharmaceuticals Inc | SELL | -3,024 @ USD 80.33 | USD -242,918 | The ETF sold 3024 shares of IONS on 2025-12-23. The shares were previously bought for an average price of USD 57.1725. The Ionis Pharmaceuticals Inc shares were sold for 40.5% higher than average price of previous purchases. This sale made a profit of USD 70,028 The average price that the ETF previously sold IONS share for is USD 48.7225 so the ETF has sold 3024 shares on 2025-12-23 at a higher price than the previous selling average. |
| GH - Guardant Health Inc | SELL | -2,412 @ USD 102.5 | USD -247,230 | The ETF sold 2412 shares of GH on 2025-12-23. The shares were previously bought for an average price of USD 69.0772. The Guardant Health Inc shares were sold for 48.4% higher than average price of previous purchases. This sale made a profit of USD 80,616 The average price that the ETF previously sold GH share for is USD 51.3955 so the ETF has sold 2412 shares on 2025-12-23 at a higher price than the previous selling average. |
| SMMT - Summit Therapeutics PLC | SELL | -13,896 @ USD 18.12 | USD -251,796 | The ETF sold 13896 shares of SMMT on 2025-12-23. The shares were previously bought for an average price of USD 20.3075. The Summit Therapeutics PLC shares were sold for -10.8% lower than average price of previous purchases. This resulted in an overall loss of USD 30,398 The average price that the ETF previously sold SMMT share for is USD 19.0425 which is higher than the selling price of USD 18.12 on 2025-12-23. |
| MDGL - Madrigal Pharmaceuticals Inc | SELL | -420 @ USD 602.21 | USD -252,928 | The ETF sold 420 shares of MDGL on 2025-12-23. The shares were previously bought for an average price of USD 414.017. The Madrigal Pharmaceuticals Inc shares were sold for 45.5% higher than average price of previous purchases. This sale made a profit of USD 79,041 The average price that the ETF previously sold MDGL share for is USD 387.181 so the ETF has sold 420 shares on 2025-12-23 at a higher price than the previous selling average. |
| VTRS - Viatris Inc | SELL | -21,504 @ USD 12.02 | USD -258,478 | The ETF sold 21504 shares of VTRS on 2025-12-23. The shares were previously bought for an average price of USD 9.93876. The Viatris Inc shares were sold for 20.9% higher than average price of previous purchases. This sale made a profit of USD 44,755 The average price that the ETF previously sold VTRS share for is USD 10.9836 so the ETF has sold 21504 shares on 2025-12-23 at a higher price than the previous selling average. |
| NBIX - Neurocrine Biosciences Inc | SELL | -1,860 @ USD 147.28 | USD -273,941 | The ETF sold 1860 shares of NBIX on 2025-12-23. The shares were previously bought for an average price of USD 135.768. The Neurocrine Biosciences Inc shares were sold for 8.5% higher than average price of previous purchases. This sale made a profit of USD 21,412 The average price that the ETF previously sold NBIX share for is USD 128.001 so the ETF has sold 1860 shares on 2025-12-23 at a higher price than the previous selling average. |
| BBIO - BridgeBio Pharma Inc | SELL | -3,600 @ USD 76.4 | USD -275,040 | The ETF sold 3600 shares of BBIO on 2025-12-23. The shares were previously bought for an average price of USD 52.3545. The BridgeBio Pharma Inc shares were sold for 45.9% higher than average price of previous purchases. This sale made a profit of USD 86,564 The average price that the ETF previously sold BBIO share for is USD 43.7847 so the ETF has sold 3600 shares on 2025-12-23 at a higher price than the previous selling average. |
| RVMD - Revolution Medicines Inc | SELL | -3,612 @ USD 80.27 | USD -289,935 | The ETF sold 3612 shares of RVMD on 2025-12-23. The shares were previously bought for an average price of USD 50.4416. The Revolution Medicines Inc shares were sold for 59.1% higher than average price of previous purchases. This sale made a profit of USD 107,740 The average price that the ETF previously sold RVMD share for is USD 50.6338 so the ETF has sold 3612 shares on 2025-12-23 at a higher price than the previous selling average. |
| ROIV - Roivant Sciences Ltd | SELL | -12,984 @ USD 22.45 | USD -291,491 | The ETF sold 12984 shares of ROIV on 2025-12-23. The shares were previously bought for an average price of USD 15.3244. The Roivant Sciences Ltd shares were sold for 46.5% higher than average price of previous purchases. This sale made a profit of USD 92,519 The average price that the ETF previously sold ROIV share for is USD 13.6297 so the ETF has sold 12984 shares on 2025-12-23 at a higher price than the previous selling average. |
| MEDP - Medpace Holdings Inc | SELL | -528 @ USD 569.7 | USD -300,802 | The ETF sold 528 shares of MEDP on 2025-12-23. The shares were previously bought for an average price of USD 446.146. The Medpace Holdings Inc shares were sold for 27.7% higher than average price of previous purchases. This sale made a profit of USD 65,237 The average price that the ETF previously sold MEDP share for is USD 388.332 so the ETF has sold 528 shares on 2025-12-23 at a higher price than the previous selling average. |
| RPRX - Royalty Pharma Plc | SELL | -7,980 @ USD 39.39 | USD -314,332 | The ETF sold 7980 shares of RPRX on 2025-12-23. The shares were previously bought for an average price of USD 36.7111. The Royalty Pharma Plc shares were sold for 7.3% higher than average price of previous purchases. This sale made a profit of USD 21,378 The average price that the ETF previously sold RPRX share for is USD 32.1248 so the ETF has sold 7980 shares on 2025-12-23 at a higher price than the previous selling average. |
| INCY - Incyte Corporation | SELL | -3,660 @ USD 100.91 | USD -369,331 | The ETF sold 3660 shares of INCY on 2025-12-23. The shares were previously bought for an average price of USD 81.7215. The Incyte Corporation shares were sold for 23.5% higher than average price of previous purchases. This sale made a profit of USD 70,230 The average price that the ETF previously sold INCY share for is USD 78.248 so the ETF has sold 3660 shares on 2025-12-23 at a higher price than the previous selling average. |
| ILMN - Illumina Inc | SELL | -2,856 @ USD 136.19 | USD -388,959 | The ETF sold 2856 shares of ILMN on 2025-12-23. The shares were previously bought for an average price of USD 105.853. The Illumina Inc shares were sold for 28.7% higher than average price of previous purchases. This sale made a profit of USD 86,642 The average price that the ETF previously sold ILMN share for is USD 116.31 so the ETF has sold 2856 shares on 2025-12-23 at a higher price than the previous selling average. |
| UTHR - United Therapeutics Corporation | SELL | -804 @ USD 510.44 | USD -410,394 | The ETF sold 804 shares of UTHR on 2025-12-23. The shares were previously bought for an average price of USD 383.252. The United Therapeutics Corporation shares were sold for 33.2% higher than average price of previous purchases. This sale made a profit of USD 102,259 The average price that the ETF previously sold UTHR share for is USD 402.815 so the ETF has sold 804 shares on 2025-12-23 at a higher price than the previous selling average. |
| ARGX - argenx NV ADR | SELL | -540 @ USD 845.95 | USD -456,813 | The ETF sold 540 shares of ARGX on 2025-12-23. The shares were previously bought for an average price of USD 719.883. The argenx NV ADR shares were sold for 17.5% higher than average price of previous purchases. This sale made a profit of USD 68,076 The average price that the ETF previously sold ARGX share for is USD 696.064 so the ETF has sold 540 shares on 2025-12-23 at a higher price than the previous selling average. |
| BIIB - Biogen Inc | SELL | -2,736 @ USD 174.82 | USD -478,308 | The ETF sold 2736 shares of BIIB on 2025-12-23. The shares were previously bought for an average price of USD 149.792. The Biogen Inc shares were sold for 16.7% higher than average price of previous purchases. This sale made a profit of USD 68,477 The average price that the ETF previously sold BIIB share for is USD 152.029 so the ETF has sold 2736 shares on 2025-12-23 at a higher price than the previous selling average. |
| INSM - Insmed Inc | SELL | -3,984 @ USD 176.77 | USD -704,252 | The ETF sold 3984 shares of INSM on 2025-12-23. The shares were previously bought for an average price of USD 142.756. The Insmed Inc shares were sold for 23.8% higher than average price of previous purchases. This sale made a profit of USD 135,512 The average price that the ETF previously sold INSM share for is USD 113.305 so the ETF has sold 3984 shares on 2025-12-23 at a higher price than the previous selling average. |
| ALNY - Alnylam Pharmaceuticals Inc | SELL | -2,460 @ USD 398.7 | USD -980,802 | The ETF sold 2460 shares of ALNY on 2025-12-23. The shares were previously bought for an average price of USD 387.87. The Alnylam Pharmaceuticals Inc shares were sold for 2.8% higher than average price of previous purchases. This sale made a profit of USD 26,642 The average price that the ETF previously sold ALNY share for is USD 298.183 so the ETF has sold 2460 shares on 2025-12-23 at a higher price than the previous selling average. |
| AZN - AstraZeneca PLC | SELL | -10,896 @ USD 92.14 | USD -1,003,957 | The ETF sold 10896 shares of AZN on 2025-12-23. The shares were previously bought for an average price of USD 79.8243. The AstraZeneca PLC shares were sold for 15.4% higher than average price of previous purchases. This sale made a profit of USD 134,192 The average price that the ETF previously sold AZN share for is USD 70.6626 so the ETF has sold 10896 shares on 2025-12-23 at a higher price than the previous selling average. |
| REGN - Regeneron Pharmaceuticals Inc | SELL | -1,932 @ USD 785.17 | USD -1,516,948 | The ETF sold 1932 shares of REGN on 2025-12-23. The shares were previously bought for an average price of USD 651.544. The Regeneron Pharmaceuticals Inc shares were sold for 20.5% higher than average price of previous purchases. This sale made a profit of USD 258,165 The average price that the ETF previously sold REGN share for is USD 685.703 so the ETF has sold 1932 shares on 2025-12-23 at a higher price than the previous selling average. |
| AMGN - Amgen Inc | SELL | -5,880 @ USD 331.49 | USD -1,949,161 | The ETF sold 5880 shares of AMGN on 2025-12-23. The shares were previously bought for an average price of USD 303.893. The Amgen Inc shares were sold for 9.1% higher than average price of previous purchases. This sale made a profit of USD 162,270 The average price that the ETF previously sold AMGN share for is USD 304.014 so the ETF has sold 5880 shares on 2025-12-23 at a higher price than the previous selling average. |
| GILD - Guild Esports Plc | SELL | -16,128 @ USD 125.19 | USD -2,019,064 | The ETF sold 16128 shares of GILD on 2025-12-23. The shares were previously bought for an average price of USD 117.641. The Guild Esports Plc shares were sold for 6.4% higher than average price of previous purchases. This sale made a profit of USD 121,750 The average price that the ETF previously sold GILD share for is USD 101.851 so the ETF has sold 16128 shares on 2025-12-23 at a higher price than the previous selling average. |
| VRTX - Vertex Pharmaceuticals Inc | SELL | -4,680 @ USD 459.21 | USD -2,149,103 | The ETF sold 4680 shares of VRTX on 2025-12-23. The shares were previously bought for an average price of USD 443.427. The Vertex Pharmaceuticals Inc shares were sold for 3.6% higher than average price of previous purchases. This sale made a profit of USD 73,864 The average price that the ETF previously sold VRTX share for is USD 471.594 which is higher than the selling price of USD 459.21 on 2025-12-23. |